1. What Exactly is a Comparative Dissolution Profile (CDP)?
A Comparative Dissolution Profile (CDP) is an in vitro performance test used to compare the drug release kinetics of a test formulation (Taj Pharma generic) against a Reference Listed Drug (RLD/LRD) under identical experimental conditions.
It is required by major regulatory agencies:
- US FDA (SUPAC-IR/MR, ANDA Guidelines)
- EMA (Guideline on Similarity of Dissolution Profiles)
- WHO
- TGA
- MHRA
- Many African/Asian authorities
The CDP determines whether two formulations release the drug:
- At similar rates
- In similar quantities
- Under biorelevant or compendial conditions
This is critical because dissolution is the first step before absorption. If two formulations dissolve similarly, they are likely to behave similarly in vivo.
2. Understanding Key Terminologies (Deep Explanation)
(A) Reference Listed Drug (RLD / LRD)
This is the innovator brand officially recognized by the drug authority as the standard comparator.
Taj Pharma procures the RLD from:
- US market (for ANDA)
- EU market (for EMA registrations)
- GCC market (for Middle East approvals)
- Local market (for CDSCO India)
The RLD is always:
- Tested with full traceability
- Stored per labelled storage conditions
- Tested for assay, ID, and dissolution before use
Meaning: The RLD itself must be quality-confirmed before being used as comparator.
(B) Therapeutic Equivalence
Regulators require two conditions:
1. Pharmaceutical Equivalence
Same:
- API
- Strength
- Dosage form
- Route
2. Bioequivalence / Expected equivalent in vivo performance
CDP is used as evidence for establishing similarity, especially for:
- BCS Class I drugs (high solubility + high permeability)
- BCS Class III drugs (high solubility + low permeability)
If CDP matches → possible biowaiver
If CDP fails → in vivo PK study is mandatory
3. Where CDP is Used in Regulatory Approval
I. ANDA Applications (US FDA)
Used for:
- SUPAC IR/MR post-approval changes
- Scale-up and site-transfer
- Bio-waiver submissions
- Formulation optimization
II. WHO PQ / EU submissions
Used when:
- Filing immediate-release oral solids
- Requesting BCS-based biowaiver
- Filing variations
III. CDSCO India
Used for:
- New drug approvals by analogy
- Generic approvals requiring comparative data
4. The f2 Similarity Factor — Deep Scientific Explanation
Regulators suggest the f2 similarity factor:f2=50×log[1+n1t=1∑n(Rt−Tt)2]−0.5×100
Where:
- Rt = % dissolution of RLD at time t
- Tt = % dissolution of Test product at time t
- n ≥ 3 time points
Interpretation
- f2 = 50–100 → profiles similar
- f2 < 50 → not similar (failure)
Regulators require:
- At least 12 units per product
- No more than one unit outside acceptance range (unusual failure)
5. Role of CDP in Granting a Biowaiver
For BCS Class I & III
If:
- Rapid dissolution (≥85% in ≤30 minutes)
- f2 similarity ≥ 50 in all three media (pH 1.2, 4.5, 6.8)
- APIs are classed as BCS-I/III
Then: In vivo BE studies may be waived.
Why regulators allow biowaivers?
Because for highly soluble drugs:
- Dissolution → not rate-limiting
- Absorption → highly predictable
- In vivo variability is minimal
Thus CDP mimics in vivo behavior.
6. Limitations of CDP (Very Important)
CDP cannot replace Bioequivalence in:
- BCS Class II drugs (low solubility)
- BCS Class IV drugs
- Modified release formulations
- Narrow therapeutic index drugs (NTI)
- Drugs with nonlinear PK
- Drugs needing fed/fasted BE studies
CDP shows similarity in vitro.
Only a PK study shows similarity in vivo.
7. How Taj Pharma Performs Comparative Dissolution Profile Studies (Step-by-Step)
Below is the actual workflow used at Taj Pharma Sarigam Plant & R&D Center (aligned with WHO-GMP, PIC/S, US FDA expectations).
STEP 1 — RLD Procurement & Verification
Taj Pharma procures RLD from:
- US / EU / Japan / Australia / Saudi / UAE
- Official distributors only
- With batch COAs, invoices, and import permits
RLD verification tests
- Identification (HPLC/GC/FTIR)
- Assay
- Related substances
- Dissolution (initial verification)
- Storage condition recording
Taj Pharma maintains import traceability documents for dossier submission.
STEP 2 — Preparation of Test Batch (Pilot Bio-Batch / Exhibit Batch)
Taj Pharma manufactures:
- Lab/Pilot scale batches for development
- Exhibit batch (10%–100% of commercial scale as per country requirement)
All batches follow:
- QbD (Quality by Design) principles
- GAMP-5 validated equipment
- Granulation parameter control
- Compression force monitoring
- Tablet hardness and porosity control
Key variables affecting dissolution are controlled:
- Particle size distribution
- Binder concentration
- Disintegrant level
- Lubricant blending time
- Compression force
STEP 3 — Dissolution Testing Setup
Performed by QC or Formulation Development Lab using:
- USP Dissolution Apparatus I (Basket) or II (Paddle)
- Temperature controlled at 37 ± 0.5°C
- USP-calibrated equipment
Media used (as per regulatory guidelines):
- pH 1.2 (Simulated gastric fluid)
- pH 4.5 (Acetate buffer)
- pH 6.8 (Phosphate buffer)
Volume: 900 mL (unless otherwise justified)
Rotation speed:
- Typically 50 rpm for paddles
- 100 rpm for baskets
Samples collected at standard time points:
0, 5, 10, 15, 20, 30, 45, 60 minutes
(or product-specific timepoints)
STEP 4 — Analytical Measurement
Samples are filtered and analyzed using:
- UV-Vis spectrophotometry
- HPLC for complex matrices
System suitability tests (SST):
- %RSD of standard not more than 2%
- Correlation coefficient r ≥ 0.999
STEP 5 — Plotting Dissolution Profiles
For each product (Test vs RLD):
- Dissolution % vs time is plotted
- 12 units each are shown
- Mean profile and ±SD bands displayed
Graph types:
- Linear profile
- % Released vs √Time
- Logarithmic scale (if required)
STEP 6 — Calculation of f2 Similarity Factor
Using validated software:
- WinNonlin
- DDSolver
- In-house validated f2 macros
Criteria:
- f2 ≥ 50 in each medium
- No single unit shows aberrant behavior
If f2 passes → profile similar
If fails → formulation redevelopment required
STEP 7 — Preparation of CDP Report for Dossier
Taj Pharma includes full CDP data in:
- CTD Module 3
- Bio-waiver justification section
- QOS (Quality Overall Summary)
Report contains:
- RLD procurement documents
- Batch manufacturing details
- Dissolution method validation
- Raw data tables (mean, SD, CV)
- f2 calculations
- Comparative graphs
- Conclusions and regulatory justification
This document is reviewed by QA and approved by the Head of R&D.
STEP 8 — Regulatory Interaction
For many countries (e.g., Philippines, GCC, LATAM, Africa), regulators may ask:
- To retest dissolution at an accredited lab
- To verify RLD information
- To provide method validation data
Taj Pharma arranges:
- Third-party testing
- Repeat CDP if requested
- Stability batch data for confirmation
8. Taj Pharma’s Strength in CDP Studies
Taj Pharma ensures:
- ISO 17025 compliant laboratories
- USP/EP/JP pharmacopoeial grade equipment
- QbD-based formulation design
- Repeatability and reproducibility
- High traceability of RLD
- Strict change control & deviation system
This makes Taj Pharma very strong in:
- Biowaiver submissions
- Regulatory inspections
- Technical partner support
- Global tender specifications
9. Summary — What CDP Proves & What It Does Not
CDP PROVES:
- Release kinetics similarity
- Tablet performance consistency
- Formulation robustness
- Possibility for biowaiver
CDP DOES NOT PROVE:
- In vivo bioequivalence for all drugs
- Clinical efficacy
- Safety profile
- Absorption in fed/fasted conditions
TAJ PHARMA – STANDARD OPERATING PROCEDURE (SOP)
Title: Comparative Dissolution Profile (CDP) Study
SOP No.: To be assigned
Version No.: 1.0
Effective Date: To be assigned
Review Date: 2 Years from Effective Date
Department: Quality Control / F&D
Supersedes: New SOP
Prepared By: ____________
Reviewed By (QC Manager): ____________
Approved By (QA Head): ____________
Distribution List: QC, QA, F&D, RA, Documentation Cell
1.0 PURPOSE
To establish a standardized, validated, and regulatory-compliant procedure for conducting Comparative Dissolution Profile (CDP) studies between the Taj Pharma test product and the Reference Listed Drug (RLD/LRD) using USP/EP/ICH guidelines and f2 similarity analysis.
This SOP ensures:
- accuracy, repeatability, and reproducibility of dissolution data
- validation of in-vitro performance similarity
- support for biowaivers, SUPAC changes, ANDA/CTD submissions, and R&D product development
2.0 SCOPE
This SOP applies to:
- Immediate-release (IR) oral solid dosage forms (tablets/capsules) of Taj Pharma
- Comparative dissolution studies against RLD or comparator products
- All tests performed in QC Laboratory and F&D analytical development lab
The SOP does not cover:
- Modified-release (MR) formulations
- IVIVC Level A/B/C modeling
- Bioequivalence studies in humans (covered under separate SOPs)
3.0 RESPONSIBILITY
3.1 QC Analyst
- Perform dissolution test as per this SOP
- Ensure equipment calibration and cleanliness
- Maintain raw data, logbooks, calculations
- Record any deviation during study
3.2 QC Supervisor
- Verify the analysis
- Review raw data and calculations
- Ensure f2 calculations are accurate
3.3 F&D Scientist
- Provide RLD data, method development inputs
- Coordinate trial batches and formulation optimization
3.4 QA Department
- Audit compliance of the test
- Review and approve final CDP report
- Manage document control and archival
4.0 DEFINITIONS
4.1 Comparative Dissolution Profile (CDP)
An in vitro comparative evaluation of % drug release vs. time for Test vs. RLD under identical conditions.
4.2 Reference Listed Drug (RLD/LRD)
The innovator product designated by regulatory agencies for comparison.
4.3 Test Product
Taj Pharma formulation (pilot, exhibit, or commercial batch).
4.4 f2 Similarity Factor
A logarithmic statistical measure used to compare dissolution profiles.
The profiles are similar if:f2=50–100
4.5 USP Apparatus I/II
I = Basket; II = Paddle.
5.0 MATERIALS AND EQUIPMENT
5.1 Equipment
- USP Dissolution Apparatus I/II (6 or 12 vessels)
- Calibrated UV-Vis or HPLC system
- pH meter (calibrated)
- Water bath (37 ± 0.5°C)
- Analytical balance
- Filter units (0.45 μm or as justified)
5.2 Reagents / Media
- pH 1.2 HCl media
- pH 4.5 acetate buffer
- pH 6.8 phosphate buffer
- Surfactants if specified (SLS/Tween 80)
- Millipore water
5.3 Documentation
- Batch manufacturing records (Test)
- Import documents for RLD
- Method development file
- Analytical method validation report
- CDP raw data sheets
- f2 calculation sheet
6.0 PROCEDURE
6.1 PRE-REQUISITES
6.1.1 Equipment Calibration
Ensure:
- Mechanical calibration of dissolution apparatus (shaft wobble, paddle depth, centering)
- Chemical calibration using USP Prednisone tablets (if applicable)
- UV/HPLC system suitability passed
6.1.2 Condition of Samples
- Test product: from approved batch; Assay within specification
- RLD: stored as per labeled storage, assay confirmed
6.2 EXPERIMENTAL DESIGN
6.2.1 Number of Units
Use 12 units each for Test and RLD.
6.2.2 Dissolution Apparatus
- USP Apparatus II (Paddle) preferred
- USP Apparatus I for capsules or as per monograph
6.2.3 Test Parameters
| Parameter | Specification |
|---|---|
| Medium | pH 1.2, pH 4.5, pH 6.8 (900 mL) |
| Temperature | 37 ± 0.5°C |
| Paddle speed | 50 rpm (unless justified) |
| Basket speed | 100 rpm |
| Sample volume | 5–10 mL |
| Time points | 0, 5, 10, 15, 20, 30, 45, 60 min |
6.2.4 Sample Withdrawal
- Withdraw at specified time points
- Replace fresh media to maintain sink conditions
- Filter using 0.45 μm filter (validate filter recovery)
6.3 SAMPLE ANALYSIS
6.3.1 UV Method
If matrix is simple (e.g., IR BCS-I/III):
- Prepare standard solution
- Check absorbance at λmax
- Ensure linearity and SST criteria
6.3.2 HPLC Method
For complex APIs:
- Validate specificity, linearity, precision
- SST criteria: %RSD ≤ 2%, resolution > 2
6.4 DATA PROCESSING AND CALCULATIONS
6.4.1 % Drug Release Calculation
Calculate % release for each unit:%Release=(AS)(WT)(At)(DF)(WS)×100
6.4.2 Mean Profile Plotting
Plot mean % release vs time for:
- Test Product
- RLD
Include standard deviation bars.
6.5 f2 SIMILARITY FACTOR CALCULATION
Use the formula:f2=50×log[1+n1t=1∑n(Rt−Tt)2]−0.5×100
Requirements:
- At least 3 time points after 85% dissolution
- CV of points ≤ 20% (early) and ≤ 10% (others)
- f2 between 50–100 = similar
If f2 fails:
- Perform root cause analysis
- Reformulate product if required
6.6 ACCEPTANCE CRITERIA
6.6.1 Regulatory Acceptance
Dissolution profiles are similar if:
- f2 ≥ 50 in all three media
- No more than one unit shows atypical behavior
- Both Test and RLD meet monograph Q value requirements
6.6.2 Biowaiver Considerations
Applicable if:
- API is BCS-I or BCS-III
- Both Test and RLD dissolve ≥85% in ≤30 minutes
- f2 ≥ 50 in all media
6.7 PREPARATION OF CDP REPORT
QC Analyst prepares full CDP report containing:
- Objective and background
- Product information (Test & RLD)
- Batch details
- Dissolution method
- Analytical method
- Raw data tables (12 units)
- Mean dissolution profiles
- f2 calculations
- Graphs and comparison plots
- Conclusion
- Attachments (COA, validation, chromatograms)
Report is:
- Reviewed by QC Manager
- Approved by QA
Submitted to:
- Regulatory Affairs
- Formulation Development
- Dossier team
7.0 DEVIATIONS
Any deviation from this SOP:
- Must be documented
- Investigated by QC
- Assessed for impact on results
- Closed before issuance of final report
8.0 SAFETY AND PRECAUTIONS
- Use PPE (lab coat, gloves, goggles)
- Handle media and solvents carefully
- Dispose of waste per EHS SOP
- Follow electrical safety for dissolution apparatus
9.0 DOCUMENTATION & RECORDS
Maintain:
- Logbooks (instrument usage, media preparation)
- Raw data sheets
- Chromatograms
- RLD procurement documents
- CDP summary report
Retention period: 5 years or as per regulatory requirement.
10.0 REFERENCES
- FDA SUPAC-IR/MR Guidance
- FDA Dissolution Testing of Immediate Release Solid Oral Dosage Forms
- EMA Guideline on the Investigation of Bioequivalence
- WHO Technical Report Series (TRS)
- ICH Q2(R1) Validation of Analytical Procedures
- USP <711> Dissolution
TAJ PHARMA – DISSOLUTION METHOD VALIDATION PROTOCOL (DVP)
Dissolution Method Validation Protocol for Comparative Dissolution Profile (CDP) Studies
Document Code: DVP–CDP–XX
Version: 1.0
Effective Date: __________
Prepared By (F&D/QC): __________________
Reviewed By (QC Manager): __________________
Approved By (QA Head): __________________
Department: Quality Control / Formulation Development
Scope: Taj Pharma Sarigam R&D & QC Lab
1.0 PURPOSE
The purpose of this protocol is to validate the dissolution analytical method used for Comparative Dissolution Profile (CDP) studies between Taj Pharma test products and the Reference Listed Drug (RLD).
The method validation ensures that the procedure is:
- Reproducible
- Accurate
- Robust
- Specific
- Suitable for regulatory submission (CTD Module 3)
Validation will follow:
- ICH Q2(R1/R2)
- USP <711> & <621>
- FDA SUPAC IR/MR guidelines
- WHO TRS 929
2.0 SCOPE
This protocol applies to:
- Immediate-release oral solid dosage forms (tablet/capsule)
- All CDP studies conducted at Taj Pharma
- Validation of dissolution method using UV or HPLC analytical detection
- Medium: pH 1.2, pH 4.5, pH 6.8 buffers
Not applicable for:
- Modified Release (MR) products
- Narrow therapeutic index (NTI) drugs (separate protocol)
- Suspensions, injectables, or semisolids
3.0 RESPONSIBILITIES
3.1 QC Analyst
- Execute the validation
- Maintain raw data, chromatograms, UV scans
- Perform calculations
3.2 QC Supervisor
- Review analytical work
- Ensure compliance with validation plan
3.3 F&D Scientist
- Provide method development data
- Support media/buffer selection
3.4 QA Head
- Approve protocol and final report
- Ensure document control and archival
4.0 VALIDATION PARAMETERS (ICH Q2 REQUIREMENT)
The following parameters will be validated:
| Parameter | Applicable |
|---|---|
| Specificity | Yes |
| Linearity & Range | Yes |
| Accuracy (Recovery) | Yes |
| Precision (Repeatability) | Yes |
| Intermediate Precision (Ruggedness) | Yes |
| Robustness | Yes |
| Filter Suitability | Yes |
| Solution Stability | Yes |
| System Suitability Testing (SST) | Mandatory |
5.0 MATERIALS & EQUIPMENT
5.1 Equipment
- USP Dissolution Apparatus I/II
- UV Spectrophotometer or HPLC system
- pH meter
- Analytical balance
- Vacuum filtration system
- Ultrasonic bath (if required)
5.2 Consumables
- 0.45 µm filters (nylon/PVDF/PTFE – must be validated)
- Volumetric flasks, pipettes
- Mobile phase solvents (HPLC grade)
- Buffer reagents (AR grade)
5.3 Chemicals
- Working Standard (Taj Pharma certified)
- Reference Standard (Pharmacopeial, if available)
- Blank media (pH 1.2, 4.5, 6.8)
6.0 VALIDATION PLAN
6.1 Specificity
Objective: Ensure the method selectively measures API in presence of excipients and media components.
Procedure:
- Analyze blank media
- Analyze placebo formulation
- Analyze sample solution
- Spike standard solution into placebo/media
Acceptance Criteria:
- No interference at λmax (for UV)
- No interfering peak at API retention time (for HPLC)
- Purity angle < purity threshold (HPLC PDA)
6.2 Linearity & Range
Objective: Establish linear relationship between absorbance/area and concentration.
Procedure:
Prepare six concentrations covering 50–150% of expected dissolution range.
For example:
- 5, 10, 20, 30, 40, 50 µg/mL
Acceptance Criteria:
- r² ≥ 0.999
- % y-intercept ≤ 2%
- Residuals random and within control
6.3 Accuracy (Recovery)
Objective: Establish closeness between measured and true values.
Procedure:
- Spike standard into dissolution media at 3 levels: 80%, 100%, 120%
- Prepare 3 replicates each
- Analyze recovery
Acceptance Criteria:
- Mean recovery: 95–105%
- RSD ≤ 2%
6.4 Precision
6.4.1 Repeatability
Analyze 6 identical samples at 100% concentration.
Acceptance Criteria:
- RSD ≤ 2% (UV)
- RSD ≤ 1% (HPLC)
6.4.2 Intermediate Precision (Ruggedness)
Repeat precision on:
- Different day
- Different analyst
- Different instrument
Acceptance Criteria:
- RSD ≤ 3%
6.5 Robustness
Objective: Assess method reliability under small deliberate variations.
Parameters to vary:
- Paddle speed: 45 & 55 rpm (±5 rpm)
- pH of media: ±0.05 units
- Temperature: 36.5–37.5°C (±0.5°C)
- Filter type changes
- Wavelength ±2 nm (UV only)
Acceptance Criteria:
- Profiles should remain similar
- Variation in % drug release ≤ 5%
6.6 Filter Suitability Study
Objective: Verify that selected filter does not adsorb drug.
Procedure:
- Prepare standard solution
- Pass through filter
- Compare:
- Filtered vs Unfiltered absorbance/area
- Test multiple filter materials
Acceptance Criteria:
- Recovery 98–102%
- No significant interference
6.7 Solution Stability
Objective: Ensure sample and standard solutions are stable during analysis.
Procedure:
- Analyze standard & sample at 0, 6, 12, and 24 hours
- Storage at room temperature (25°C)
- Use identical conditions
Acceptance Criteria:
- Assay variation ≤ 2% over 24 hours
6.8 System Suitability Testing (SST)
For UV:
- Absorbance RSD for 6 scans ≤ 1%
- Baseline stability within limits
For HPLC:
- %RSD of six injections ≤ 1%
- Retention time RSD ≤ 1%
- Theoretical plates ≥ 2000
- Tailing factor ≤ 2.0
7.0 VALIDATION ACCEPTANCE TABLE
| Validation Test | Requirement | Pass Criteria |
|---|---|---|
| Specificity | No interference | Meets criteria |
| Linearity | r² ≥ 0.999 | Linear curve |
| Accuracy | 95–105% | Within limits |
| Repeatability | RSD ≤ 2% | Pass |
| Ruggedness | RSD ≤ 3% | Pass |
| Robustness | Variation ≤ 5% | Pass |
| Filter Suitability | 98–102% | Pass |
| Solution Stability | Variation ≤ 2% | Pass |
| SST | As per method | Pass |
8.0 DEVIATION MANAGEMENT
Any deviation from this protocol must:
- Be documented in the deviation form
- Investigated by QC
- Assessed by QA for impact
- Closed before issuing final validation report
If deviation impacts results → method revalidation may be required.
9.0 DOCUMENTATION & RECORDS
The following documents will be generated:
- Raw data sheets
- Calibration certificates
- UV/HPLC chromatograms
- Linearity, precision, accuracy worksheets
- Filter suitability report
- SST data
- Validation summary report
Retention: Minimum 5 years or as per regulatory requirement.
10.0 APPROVALS
| Role | Name | Signature | Date |
|---|---|---|---|
| Prepared By | |||
| Reviewed By | |||
| Approved By |
TAJ PHARMA – VALIDATION REPORT (VR)
Dissolution Method Validation Report for Comparative Dissolution Profile (CDP) Studies
Document Code: VR–CDP–XX
Version: 1.0
Effective Date: __________
Prepared By (QC/F&D): __________________
Reviewed By (QC Manager): __________________
Approved By (QA Head): __________________
Department: Quality Control
Site: Taj Pharma, Sarigam, Gujarat
1.0 INTRODUCTION
This Validation Report summarizes the execution, results, and conclusions of the Dissolution Method Validation Protocol (DVP–CDP–XX) performed for the Comparative Dissolution Profile (CDP) method developed for:
Product Name: __________________________
Strength: __________________________
Dosage Form: Immediate Release Tablet/Capsule
API: __________________________
The purpose of this validation was to confirm that the developed dissolution method is suitable, reproducible, accurate, precise, and robust for its intended use in comparing Taj Pharma test products with the RLD/innovator product.
The validation was performed as per:
- ICH Q2(R1/R2)
- USP <711> Dissolution
- USP <621> Chromatography
- FDA SUPAC & Biowaiver Guidelines
- WHO TRS 929 Method Validation Guidance
2.0 SUMMARY OF VALIDATION PROTOCOL EXECUTION
| Item | Details |
|---|---|
| Protocol No. | DVP–CDP–XX |
| Execution Period | From: ____ To: ____ |
| Executor | QC Analyst |
| Reviewer | QC Manager |
| Approver | QA Head |
| Validation Type | Full Method Validation |
| Detection Technique | UV / HPLC (Specify) |
All validation experiments were performed exactly as described in the approved protocol unless deviations (if any) were documented.
3.0 SAMPLE AND REAGENT DETAILS
3.1 Working Standard
- Name: _________________________________
- Batch/Lot No.: __________________________
- Potency (%): __________________________
- Source: Taj Pharma QC / Pharmacopeial
3.2 Media Used
- pH 1.2 HCl Buffer
- pH 4.5 Acetate Buffer
- pH 6.8 Phosphate Buffer
- Volume: 900 mL
- Temp: 37 ± 0.5°C
3.3 Equipment
- Dissolution Apparatus I/II (Make/Model: ____________________)
- UV/HPLC System (Make/Model: ____________________)
- pH Meter (Make/Model: ____________________)
- Analytical Balance
All equipment were calibrated and verified before use.
4.0 VALIDATION PARAMETERS AND RESULTS
4.1 SPECIFICITY
Objective:
To ensure no interference from media or placebo during quantification.
Samples Tested:
- Blank media
- Placebo
- Standard
- Test sample
- Spiked solution
Results Summary:
| Sample | Interference Observed | Conclusion |
|---|---|---|
| Blank | No | Pass |
| Placebo | No interfering peak/λ | Pass |
| Standard | Clear peak/λ | Pass |
| Sample | Clear | Pass |
| Spiked | Recovery within limits | Pass |
Conclusion:
Method is specific for API quantification.
4.2 LINEARITY & RANGE
Linearity Levels: 50–150%
Number of Points: 6
| Concentration Level | Concentration (µg/mL) | Response |
|---|---|---|
| Level 1 | ||
| Level 2 | ||
| Level 3 | ||
| Level 4 | ||
| Level 5 | ||
| Level 6 |
Regression Statistics:
- Slope: __________
- Intercept: __________
- r²: __________ (Should be ≥ 0.999)
- % y-intercept: __________
Conclusion:
Linearity is established.
4.3 ACCURACY (RECOVERY)
Recovery Levels: 80%, 100%, 120%
| Level | % Recovery | % RSD | Conclusion |
|---|---|---|---|
| 80% | Pass | ||
| 100% | Pass | ||
| 120% | Pass | ||
| Overall Mean | ≤2% | Pass |
Conclusion:
Method is accurate.
4.4 PRECISION
4.4.1 Repeatability
Six replicate analyses performed.
| Sample No. | Result (% Release) |
|---|---|
| 1 | |
| 2 | |
| 3 | |
| 4 | |
| 5 | |
| 6 |
- Mean: ______
- % RSD: ______ (Acceptance ≤ 2%)
Conclusion:
Repeatability is proven.
4.4.2 Intermediate Precision (Ruggedness)
Performed by:
- Different Analyst
- Different Day
- Different Instrument (if applicable)
| Parameter | Result |
|---|---|
| Mean | ______ |
| % RSD | ______ (≤ 3%) |
| Conclusion | Pass |
Conclusion:
Method is rugged.
4.5 ROBUSTNESS
Parameters Varied:
- Paddle speed ±5 rpm
- Temperature ±0.5°C
- pH ±0.05 units
- Filter type
- UV/HPLC wavelength ±2 nm
| Condition | Result Variation | Pass/Fail |
|---|---|---|
| Paddle 45 rpm | ||
| Paddle 55 rpm | ||
| Temp 36.5°C | ||
| Temp 37.5°C | ||
| pH modification | ||
| Filter check | ||
| Wavelength shift |
Conclusion:
Method is robust.
4.6 FILTER SUITABILITY
| Filter Type | Recovery (%) | Pass/Fail |
|---|---|---|
| Nylon 0.45 µm | ||
| PTFE 0.45 µm | ||
| PVDF 0.45 µm |
Conclusion:
Selected filter is suitable.
4.7 SOLUTION STABILITY
| Time Point | Standard (%) | Sample (%) | Acceptance (≤2% deviation) |
|---|---|---|---|
| 0 hr | |||
| 6 hr | |||
| 12 hr | |||
| 24 hr |
Conclusion:
Solutions are stable up to 24 hours.
4.8 SYSTEM SUITABILITY TESTING (SST)
For UV:
- Absorbance RSD ≤ 1%
- Baseline stable
For HPLC:
- %RSD of 6 injections ≤ 1%
- Tailing factor ≤ 2
- Theoretical plates ≥ 2000
Conclusion:
System suitability met all specifications.
5.0 SUMMARY & OVERALL CONCLUSION
Based on the results obtained and the acceptance criteria defined in the approved DVP, the dissolution method for:
Product: ________________________
Strength: ________________________
is VALIDATED for use in:
✔ Comparative Dissolution Profile (CDP) studies
✔ f2 similarity factor calculations
✔ Biowaiver justification
✔ Routine QC dissolution testing
✔ Regulatory submission (CTD Module 3.2.P.5)
The method is:
- Specific
- Linear
- Accurate
- Precise
- Rugged
- Robust
- Stability-compliant
- Filter-verified
Therefore, the method is suitable for its intended purpose.
6.0 DEVIATIONS (IF ANY)
| Deviation No. | Description | Impact Assessment | Corrective Action |
|---|---|---|---|
| 1 | |||
| 2 |
Conclusion: All deviations were closed and did not impact method validity.
7.0 ATTACHMENTS / ANNEXURES
- Approved Validation Protocol (DVP–CDP–XX)
- Raw data sheets
- UV/HPLC chromatograms
- Linearity graphs
- Accuracy worksheets
- Precision worksheets
- Robustness worksheets
- Filter suitability results
- SST reports
- Calibration certificates
- Final CDP method SOP (reference)
8.0 APPROVALS
| Role | Name | Signature | Date |
|---|---|---|---|
| Prepared By | |||
| Reviewed By | |||
| Approved By |
Regulatory Biowaiver Justification Note
Taj Pharma – Comparative Dissolution & BCS-Based Biowaiver Justification
1. Introduction
This justification note supports the request for a biopharmaceutics classification system (BCS)–based biowaiver for the proposed generic formulation manufactured by Taj Pharmaceuticals Ltd. The biowaiver is sought in accordance with regulatory guidelines issued by:
- WHO Technical Report Series (Annex 8)
- US FDA Guidance for Industry on Waivers of In Vivo Bioavailability and Bioequivalence Studies
- EMA Guideline on BCS-Based Biowaivers (2020)
- ICH M9: Biopharmaceutics Classification System–Based Biowaivers
The objective of this submission is to demonstrate that the in vitro dissolution profile of the Test product is similar to the Reference Listed Drug (RLD) and that in vivo bioequivalence studies can be waived owing to the scientific justification under the BCS framework.
2. Basis for Biowaiver Request
The biowaiver request is based on three pillars required by global regulatory agencies:
- BCS Classification of API (Class 1 or Class 3)
- Rapid and similar in vitro dissolution profile across multiple media
- Qualitatively (Q1) and Quantitatively (Q2) similar formulation
- Robust risk assessment demonstrating low risk of in vivo variability
3. BCS Classification and Scientific Justification
3.1 Solubility Assessment
The API demonstrates high solubility across the physiological pH range (1.2, 4.5, 6.8), meeting the requirement that the highest dose strength dissolves in ≤ 250 mL aqueous media.
- Highest strength dose solubility: <<Insert data>>
- Meets regulatory definition of “highly soluble.”
3.2 Permeability Assessment
Depending on the API:
- BCS Class 1: High solubility & high permeability.
- BCS Class 3: High solubility & low permeability but rapidly dissolving product can still qualify.
Permeability demonstrated via:
- Human mass-balance study
- Absolute bioavailability studies
- In vitro permeability models (Caco-2) where applicable
=> The API meets criteria for “high permeability” (for Class 1) or “sufficient regulatory acceptance” (for Class 3).
4. Formulation Comparison (Q1/Q2 Similarity)
4.1 Qualitative Similarity (Q1)
The test product uses the same excipients as the RLD.
4.2 Quantitative Similarity (Q2)
All excipients are present in amounts within the regulatory-acceptable variations:
- Differences within ±10% w/w where applicable
- Functional categories of excipients remain unchanged
- No excipients likely to affect absorption
Thus, Q1/Q2 criteria are met in accordance with FDA/EMA/WHO guidelines.
5. In Vitro Dissolution Comparison
5.1 Dissolution Media
Dissolution testing was conducted in:
- 0.1N HCl (pH 1.2)
- Acetate Buffer (pH 4.5)
- Phosphate Buffer (pH 6.8)
at 900 mL, 37°C ± 0.5°C using USP Apparatus II.
5.2 Results Summary
- Both Test and RLD showed rapid dissolution (>85% in 15 minutes)
→ qualifies automatically for similarity per WHO/FDA. - When >85% is not achieved within 15 min, f2 analysis applied:
5.3 Similarity Factor (f2)
- f2 value between Test vs Reference in all three media:
→ f2 = <<Insert values>> (≥ 50) - Demonstrates statistically significant similarity.
5.4 Profile Consistency
- Minimal variability across six units
- Robust profile without risk of dose dumping or excipient impact
6. Risk Assessment for Biowaiver Eligibility
A detailed Quality Risk Management (QRM) assessment was conducted per ICH Q9.
| Risk Parameter | Assessment | Conclusion |
|---|---|---|
| Excipients Influence | No critical impact | Acceptable |
| Manufacturing Process | Standard, non-critical | Low risk |
| Dissolution Sensitivity | Not sensitive to minor variations | Acceptable |
| Food effect | No significant food effect in RLD | Low clinical risk |
| Narrow Therapeutic Index (NTI) | API is not NTI | Eligible |
→ Risk is low and bioequivalence is unlikely to be affected.
7. Regulatory Alignment
7.1 FDA
Meets conditions in FDA’s BCS Biowaiver Guidance for Class 1 and 3 drugs.
7.2 EMA
Conforms to EMA BCS Biowaiver requirements:
- High solubility
- Rapid dissolution
- Q1/Q2 sameness
- f2 ≥ 50
7.3 WHO
Complies with WHO TRS Annex 8 requirement for:
- Rapid dissolution
- Non-critical excipients
- BCS class suitability
8. Conclusion
Based on:
- High solubility and acceptable permeability
- Q1/Q2 formulation sameness
- Rapid and similar dissolution in all media
- High f2 similarity values
- Low risk of in vivo variability
The Test product manufactured by Taj Pharma India Ltd. meets all regulatory criteria for a BCS-based biowaiver.
Therefore, in vivo bioequivalence studies are not required, and the product is eligible for a biowaiver submission under CTD Module 3.2.P.2.
9. Attachments
(Provided as Annexures in CTD Module 3)
- Comparative Dissolution Profile (CDP) report
- f2 calculation sheets
- Q1/Q2 formulation comparison table
- API solubility data
- Permeability study data
- Dissolution raw data sheets
- Risk Assessment (ICH Q9)






